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Colorectal cancer (CRC) is one of the most common malignancies in the world. The development and 
progression of CRC is a multistep process, which involves many dietary and environmental factors. A 
great number of oncogenes, tumour suppressor genes and DNA repair genes contribute to molecular 
and biological features of CRC, providing us much essential information about the pathogenesis of this 
disease. Loss of heterozygosity (LOH) of tumour suppressor genes was observed at various loci on 
different chromosomes like 1p, 1q, 4q, 5q, 8p, 9q, 11q, 12p, 14q, 15q, 17p, 17q, 18p, 18q and 22q in 
CRCs. In this review, the loss of heterozygosity in patients with colorectal cancer and the 
interrelationship between tumour suppressor genes and colorectal cancer initiation and progression 
are discussed. 
 





Colorectal cancer (CRC) is the third most common cause 
of death in the world (Shibuya et al., 2002).  Cases of 
CRC can be classified as sporadic (75%), familial (20%) 
and genetic syndromes such as Hereditary Nonpolyposis 
Colorectal Cancer (HNPCC) and Familial Adenomatous 
Polyposis (FAP) (5%) (Hendon and Dipalma, 2005). CRC 
develops as the result of the progressive accumulation of 
genetic and epigenetic alterations that lead to the trans-
formation of normal colonic epithelium to colorectal 
adenocarcinoma (Grady, 2005). CRC occurs through a 
multi-step process, which is characterized by the 
inactivation of tumour suppressor genes and activation of 
proto-oncogenes by mutations and/or allelic loss or 
mismatch repair deficiency (Fransen et al., 2004). The 
risk of getting colorectal cancer increases with age. 
Nearly 90% of colorectal cancer patients are over the age 
of 50 (Robins and Kumar, 1987). 
As allelic loss at a certain region of chromosome is 
thought to indicate the presence of a tumour suppressor 
gene, loss of heterozygosity (LOH) analysis is presently 
the most common method used to identify potential loca-
tions for these genes. Although LOH is a common phe-
nomenon in a variety of human cancers, a high frequency 
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location of a candidate tumour suppressor gene. Accor-
ding to this hypothesis, there are still several undis-
covered tumour suppressor genes that play potentially 
important roles in cancer development (Pylkkänen, 
2002). Genome-wide searches for LOH have been per-
formed successfully to localize putative tumour suppres-
sor gene loci. The observation that LOH may have 
prognostic implications has created a situation in which 
the study of this abnormality provides information 
significant enough to suggest that, for clinical purposes, 
tumours of certain types should be typed routinely for 
LOH at specific loci (Massa et al., 1999).  
LOH analysis is a sensitive genetic method that is used 
to detect micro deletions on chromosomes. A frequent 
deletion in a chromosomal region may suggest the 
existence of a candidate tumour suppressor gene (Cetin 
et al., 2008). Here, we reviewed the positive correlation 
between tumour suppressor genes and CRC develop-
ment. In consequence, the importance of LOH needs to 





Colorectal cancer is one of the four most prevalent 
cancer types in the world, which affects the majority of 
elderly people (Boyle and Langman, 2000). A cascade of 
cellular, biochemical and genetic events is known to 





leading to malignancy and ultimately metastatic dissemi-
nation. In all human cancers, the molecular genetic alte-
rations in colorectal cancer are among the best under-
stood (Kapitanovic et al., 2004). Colorectal carcino-
genesis is a multistep process in which a series of gene-
tic and epigenetic events leads to the transition from 
normal mucosa polyps to carcinoma. Together, these 
events allow cells to bypass several of the normal regula-
tory processes and develop traits specific to malignant 
cells, such as limitless replication, evasion of apoptosis 
and tissue invasion. Because the spontaneous somatic 
mutation rate is not sufficient to account for such a 
number of mutations, acquisition of a mutant phenotype 
is generally presumed to be an early event in tumour pro-
gression, with additional mutant phenotypes likely to 
enter later in its progression. This development is most 
likely the result of mutations or losses in genes that 
maintain genetic stability by mediating precise replication, 
damage repair, or checkpoint activation (Brenner et al., 
2007). Colorectal tumorigenesis is a multistep process in 
which many oncogenes and tumour suppressor genes 
are involved (Cacev et al., 2005; Zheng et al., 2005).  
Colorectal cancer represents a group of heterogeneous 
epithelial malignancies, of which familial adenomatous 
polyposis coli (FAP) and hereditary nonpolyposis colon 
cancer (HNPCC) are two major colorectal cancer predis-
position syndromes. FAP is usually present in the second 
decade of life and is characterized by the presence of 
100s to 1000s of adenomatous polyps carpeting the large 
bowel. Malignant change usually takes place in one or 
more polyps after age 50. Almost all FAP cases result 
from truncating mutations in the APC gene. In contrast, 
HNPCC patients have a normal or only slightly elevated 
tendency to develop adenomas, but the probability and 
rate of progression to carcinoma is increased and an 
increased risk of other carcinomas is also a recognizable 
feature of this syndrome. Germ line defects, in one or 
more of a group of DNAm mismatching repair genes such 
as MLH1, MSH2, MLH3, PMS1, PMS2, MSH6 and 
GTBP, are associated with HNPCC. Approximately 15% 
of colorectal cancer is caused by dominantly inherited 
predisposition to the disease. Only 2 – 6% of cases have 
been attributed to FAP or HNPCC, suggesting the 




TUMOUR SUPPRESSOR GENES AND LOSS OF 
HETEROZYGOSITY 
 
Cancer results from successive accumulation of alte-
rations in essential genes that play important roles in cell 
signaling, proliferation, apoptosis, invasion, or angio-
genesis. Some of these genes get over expressed, pro-
ducing abundant supply of their gene products, whereas 
others are suppressed or even deleted. Genes of the 
former group, in which alterations lead to gain of function,  




are the so-called oncogenes. Oncogenes are variations 
of normal genes (proto-oncogenes) that play important 
roles in normal cells by activating cell signaling or prolife-
ration. These genes become active because of specific 
abnormalities such as gene amplification, over expres-
sion, point mutation, insertion mutation, or translocation 
(Velasco et al., 2008). 
A second group of genes involved in cancer develop-
ment and progression are tumour suppressor genes 
(TSGs) (Velasco et al, 2008). TSGs have a normal 
physiological role of retarding cell division. TSGs work 
with the DNA repair system, which makes them neces-
sary in the maintenance of host genetic stability. TSGs in 
mutated form can be passed on as germline heritable 
DNA defects. They are the cause of syndromes of gene-
tic predisposition to cancer (Ross, 1998).  
Inactivation of TSGs causes cells to display one or 
more phenotypes of neoplastic growth. Knudson’s defini-
tion of a classical tumour suppressor gene requires the 
inactivation of both alleles of a candidate gene in 
tumours. Inactivation of these classical TSGs usually 
occurs either in the deletion of the one own allele or 
mutation in the rest alleles. However, a new class of 
TSGs with haploid insufficiency, in which one allele is lost 
and the remaining allele is haploid sufficient, has been 
described recently and these hemizygous tumour 
suppressor genes show a tumour-prone phenotype when 
challenged with carcinogens (Knudson, 1971; Gunduz et 
al., 2005). 
Several tumour suppressor genes associated with colo-
rectal carcinoma have been identified: these include 
TSGs mutated in colon cancer (MCC) and adenomatous 
polyposis coli (APC) on chromosome 5q, p53 on chro-
mosome 17p, nm23-H1 on chromosome 17q, and TSGs 
deleted in colon cancer (DCC) and deleted in pancreatic 
carcinoma (DPC4) on chromosome 18q. The adeno-
matous polyposis coli (APC) tumour suppressor gene 
was identified 10 years ago through its association with 
an inherited syndrome of colorectal cancer known as 
familial adenomatous polyposis coli (FAP). APC is 
mutated in the germ-line DNA of patients with familial 
adenomatous polyposis. Somatic mutations or allelic 
deletions of APC, or both, have also been described in 
sporadic colorectal cancer (Kapitanovic et al., 2004).  
One of the critical steps for the identification of TSGs is 
loss of heterozygosity analysis (LOH) (Gunduz et al., 
2005). LOH, identified by comparing patterns of polymor-
phisms in normal and tumour cells from one individual 
(Cacev et al., 2006), is observed at many loci in tumours. 
LOH of tumour suppressor genes is believed to be one of 
the key steps to carcinogenesis of colorectal cancer. 
LOH, the loss of one allele at a specific locus, is caused 
by a deletion mutation or loss of a chromosome from a 
chromosome pair. When this occurs at a tumour sup-
pressor gene locus where one of the alleles is already 
abnormal, it can result in neoplastic transformation 
(Zheng et al., 2005;   Zhou et al., 2008;  Wan et al., 2006;  




Zhou et al., 2004). At loci showing LOH, two alleles are 
observed in normal cells, while only one allele is detected 
in tumour cells because the other has been lost (Cacev et 
al., 2006).  
Loss of heterozygosity can be identified in cancers by 
noting the presence of heterozygosity at a genetic locus 
in an organism's germline DNA and the absence of hete-
rozygosity at that locus in the cancer cells. This is often 
done using polymorphic markers, such as microsatellites 
or single nucleotide polymorphisms, for which the two 
parents contributed different alleles (Cacev et al., 2006). 
 
 
COLORECTAL CANCER AND LOSS OF 
HETEROZYGOSITY 
 
Loss of heterozygosity in colorectal cancer was first 
reported by Vogelstein et al. (1989). It was then explored 
by many investigators. Attempts to establish the relation-
ship between colorectal cancers and allele losses at 
different chromosome loci have been made. In one study 
aimed to screen LOH in the colorectal cancer, the fre-
quency of allelic losses were determined at 17p (28%), 
18p (26%), 18q and 5q (25%), 9q and 15q (24%), 8p 
(23%) and 14q (20%) throughout the genome (Mao et al., 
2006). Nevertheless, Mao et al. (2006) reported six diffe-
rent LOH areas as 4q (42%), 1p (36%), 11q (31%), 17p 
(28%), 18p (26%) and 1q (25%) in sporadic colorectal 
carcinoadenomas.  
PTPRJ (protein tyrosine phosphatise receptor type J) 
on chromosome band 11p11 is a gene exposed to dele-
tion among several cancer types including colorectal can-
cer. Ruivenkamp et al. (2003) reported a strong correla-
tion between the LOH of PTPRJ and the loss of chromo-
somal region 18q12-21 in a more progressed form of 
colorectal adenomas (Ruivenkamp et al., 2003).     
In a study, allele loss at 15q14-q22 was studied in 277 
cases of early-onset colorectal cancers using four micro-
satellite markers (D15S970, D15S117, D15S971 and 
D15S1028) (Popat et al., 2003).  
The observation of high frequency LOH on chromo-
some 1 in patients with sporadic colorectal cancer by 
Zhou et al. (2004) may suggest the presence of putative 
tumour suppressor genes associated with sporadic 
colorectal cancer on 1p36.31-36.33. TP73, a member of 
p53 gene family located on chromosome 1p36, is a 
tumour suppressor gene (Kapiteijn et al., 2001). How-
ever, due to the fact that many other genes are also 
located in 1p36, the effect of TP73 on colorectal carconi-
genesis needs to be further determined (Zhou et al., 
2004). In another study on long arm of chromosome-1, 
(1q31.1-32.1), high-frequency LOH was determined in 
sporadic colorectal carcinoma. No significant association 
between clinic pathological findings (patient gender, age, 
tumour size and the stages of tumour) and LOH in each 
selected marker was observed. One or more tumour 





region. After searching databases, CSRP1 was pre-
sumed to be involved in the carcinogenesis of colorectal 
carcinoma. However, no functional evidence exists (Zhou 
et al., 2008).  
The neurofibromatosis type 1 (NF1) gene is a large 
gene located on chromosome 17q11.2. The NF1 protein 
turns active form of Ras protein into an inactive form. A 
well-defined transition is needed from NF1 to Ras. Ras 
protein plays a central role in cellular growth and 
differentiation and its aberrant activation is involved in the 
development of a variety of human cancers. Negative 
regulation of Ras activity classifies NF1 gene as a tumor 
suppressor gene (Cacev et al., 2005). Loss of hetero-
zygosity at NF1 locus was determined in colon tumor 
tissues. NF1 isoform type I was found to significantly in-
crease in tumor tissue compared with normal tissue. 
Thus, NF1 isoform type I may play a role in the develop-
ment and progression of colon cancer (Cacev et al., 
2005). 
Loss of heterozygosity on long arm of chromosome 22 
was also investigated. In these studies, LOH on chromo-
some 22 was observed in the oral (40%), brain (40%), 
ovarium (55%), breast (40%), pancreatic endocrine 
(30%) tumours and gastrointestinal stromal tumours 
(77%). An allele loss at average rate of 28.38% on 22q13 
region was also reported in colorectal cancer (Zheng et 
al., 2005). 
Chang et al. (2005) investigated prognostic value and 
frequency of LOH at 14 genetic loci near regions con-
taining important genes in colorectal cancer formation. In 
one of such genetic locus, LOH occurred in 78.8% of the 
tumours. Regions observed at highest frequency of LOH 
were determined as tumour suppressor gene locus 
(TP53.alu (65%), DCC (64.3%), D8S254 (51.7%) and 
APC (47.8%)) (Chang et al., 2005). High-frequency LOH 
was also found to correlate with high metastatic potential 
of colorectal cancers. In another study, the relationship 
between LOH in regions where APC and DCC genes are 
located and micro metastasis in per colonic lymph nodes 
was also studied (Zauber et al., 2004) and no correlation 
was found. However, Tanaka et al. showed interaction 
between LOH of region 18q21 in colorectal cancers and 
lymph node metastasis (Tanaka et al., 2008). Parallel 
results from different studies may suggest a positive 
correlation between loss of heterozygosis and the 
metastasis potential of colorectal cancers. 
While the positive correlation between clinic patho-
logical findings and LOH in colorectal cancers was shown 
in some studies, the prognostic value of LOH is still not 
clear. To determine the correlation between allele loss at 
the BRCA1 locus and patient prognosis in sporadic 
colorectal cancers, Garcia et al. (2003), reported that the 
1st and 2nd stages of LOH in gene locus BRCA1 could 
be used as a free prognostic factor for colorectal cancer. 
In one study 40 microsatellite markers in eight cancer-
related chromosomes 3p, 4p, 5q, 8p, 9p, 13q, 17p and 





found to correlate with clinical and pathological findings 
(Choi et al., 2002). In another study, Kapitanovic et al. 
(2004) detected LOH at the APC gene loci in 30.1% of 
tumours examined. The APC gene LOH was significantly 
higher in B stage of the Dukes (55.6%) and in the 
moderately differentiated tumours (Kapitanovic et al., 
2004). 
Activated Ras proto-oncogenes, especially Kras2, play 
an important role in the carcinogenesis. Mutation of 
Kras2 gene was detected in breast, rectum, stomach, 
pancreas, ovarian, lung and liver tumours (Wan et al., 
2006). Wan et al. reported allele losses in chromosome 
region 12p12-13 where Kras2 gene is located in Chinese 
colon carcinoma tissues. Just like other studies, in this 
study no correlation was observed between the occur-
rence of LOH and age, patient sex, size of tumour and 
metastases of cancer cells (Wan et al., 2006). In another 
study, no correlation was found between clinic patho-
logical findings and LOH observed in loci D4S3013 
(4p15.2) and D4S405 (4p14) (Zheng et al., 2005). 
CRC develops after a long carcinogenesis cycle and 
multiple stages. A number of tumour suppressor genes 
are involved in this process. Some are shown to be corre-
lated with the progression of colorectal cancer. However, 
it is possible that many unidentified tumour suppressor 
genes may exist. In these studies, the correlation bet-
ween LOH analyses and candidate tumour suppressor 
genes, as well as their roles in the tumorigenesis of colo-
rectal cancer were investigated. However, clinical and 
pathological findings are also important for the progress-
sion of colorectal cancers like that in other cancers. In 
this review, the correlation between clinical and patho-
logical findings with allele losses on various chromosome 
regions in colorectal cancer was discussed. As a result, 
the candidate tumour suppressor genes can be deter-
mined by LOH analyses. In addition, allele losses chro-
mosome regions, where candidate tumour suppressor 
genes are located, may be important in terms of the pro-
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